Charlotte Poile

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial

Dean A. Fennell, Sean Ewings, Christian H. Ottensmeier et al. · The Lancet Oncology · 2021 · 259 citations · Full text

Medicine, Oncology, Pharmacology +15

Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment

Min Zhang, Jinli Luo, Qianqian Sun et al. · Nature Communications · 2021 · 128 citations · Full text

Medicine, Cancer Biology, Oncology +17

Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial

Dean A. Fennell, Charlotte Poile, Molly Scotland · The Lancet Respiratory Medicine · 2021 · 113 citations

Medicine, Oncology, Pharmacology +11

A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study

Elizabeth Bancroft, Elizabeth Page, Mark N. Brook et al. · The Lancet Oncology · 2021 · 93 citations · Full text

Life Sciences, Genetics, Oncology +17

Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial

Dean A. Fennell, Amy King, Seid Mohammed et al. · The Lancet Oncology · 2022 · 81 citations · Full text

Medicine, Oncology, Pharmacology +8